Technical Analysis for INMB - INmune Bio Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Down | Up |
| See historical INMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 3.08% | |
| Oversold Stochastic | Weakness | 3.08% | |
| Lower Bollinger Band Walk | Weakness | 15.69% | |
| Wide Bands | Range Expansion | 15.69% | |
| Oversold Stochastic | Weakness | 15.69% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
Biotechnology Cancer Disease Immunotherapy Solid Tumors Immune System Cancer Treatments Hematologic Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Checkpoint Inhibitor
Biotechnology Cancer Disease Immunotherapy Solid Tumors Immune System Cancer Treatments Hematologic Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Checkpoint Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more INMB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 11.5 |
| 52 Week Low | 3.505 |
| Average Volume | 29,425 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 5.5627 |
| 20-Day Moving Average | 4.8686 |
| 10-Day Moving Average | 4.1813 |
| Average True Range | 0.3738 |
| ADX | 37.58 |
| +DI | 14.5805 |
| -DI | 31.1348 |
| Chandelier Exit (Long, 3 ATRs ) | 4.9686 |
| Chandelier Exit (Short, 3 ATRs ) | 4.6264 |
| Upper Bollinger Band | 6.3982 |
| Lower Bollinger Band | 3.339 |
| Percent B (%b) | 0.33 |
| BandWidth | 62.835312 |
| MACD Line | -0.5676 |
| MACD Signal Line | -0.5388 |
| MACD Histogram | -0.0288 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.89 | ||||
| Resistance 3 (R3) | 4.84 | 4.62 | 4.80 | ||
| Resistance 2 (R2) | 4.62 | 4.48 | 4.64 | 4.77 | |
| Resistance 1 (R1) | 4.48 | 4.39 | 4.55 | 4.53 | 4.74 |
| Pivot Point | 4.26 | 4.26 | 4.29 | 4.28 | 4.26 |
| Support 1 (S1) | 4.12 | 4.12 | 4.19 | 4.17 | 3.96 |
| Support 2 (S2) | 3.90 | 4.03 | 3.92 | 3.93 | |
| Support 3 (S3) | 3.76 | 3.90 | 3.90 | ||
| Support 4 (S4) | 3.81 |
